Improved management of primary chronic fatigue syndrome with the supplement French oak wood extract (Robuvit®): a pilot, registry evaluation. — CFSMEATLAS
Improved management of primary chronic fatigue syndrome with the supplement French oak wood extract (Robuvit®): a pilot, registry evaluation.
Belcaro, G, Cornelli, U, Luzzi, R et al. · Panminerva medica · 2014
Quick Summary
This small study tested whether a supplement made from French oak wood extract (Robuvit®) could help people with chronic fatigue syndrome (CFS) when combined with a structured management plan. About half of the 91 participants received the supplement for 6 months while the other half followed the management plan alone. The supplement group showed greater improvements in fatigue symptoms and mood compared to the management-only group, and no side effects were reported.
Why It Matters
ME/CFS has no approved treatments and patients often receive limited clinical support; this study suggests that targeting oxidative stress with a supplement, combined with structured management attention, may improve symptoms and mood. The finding of elevated oxidative stress in a majority of CFS participants adds to growing evidence of metabolic dysfunction in the disease. However, larger, rigorously controlled trials are needed before recommending this supplement to patients.
Observed Findings
Oxidative stress decreased significantly in the Robuvit® group at 3 and 6 months but showed no significant change in controls.
CFS symptom scores improved significantly in the Robuvit® group across main and accessory symptoms after 3 and 6 months; controls also improved but less markedly.
Mood improved substantially in the Robuvit® group (from −6.93 to +4.32 on the BMIS) compared to modest improvement in controls (from −6.5 to −3.4).
Three of 48 participants (6.3%) dropped out of the Robuvit® group and 3 of 43 (7.0%) dropped out of controls, with 93% capsule compliance reported.
No adverse effects were observed during 6 months of supplementation.
Inferred Conclusions
French oak wood extract supplementation combined with a management plan offers symptom and mood benefits greater than management alone in CFS patients, particularly those with elevated oxidative stress.
Oxidative stress reduction may be one mechanism by which Robuvit® improves CFS symptoms, though this requires further investigation.
The supplement appears safe and well-tolerated in CFS populations.
Remaining Questions
Does the benefit of Robuvit® persist beyond 6 months, and what is the optimal long-term dosing?
What This Study Does Not Prove
This study does not prove that Robuvit® causes symptom improvement—the control group also improved substantially, making it unclear how much benefit comes from the supplement versus increased clinical attention and a structured plan. The small sample size, lack of randomization and blinding, and registry design (not a randomized controlled trial) mean the findings are preliminary and cannot establish causation. Whether oxidative stress is a cause or consequence of CFS remains unclear.
Tags
Symptom:Cognitive DysfunctionPainFatigue
Biomarker:Blood Biomarker
Method Flag:PEM Not DefinedWeak Case DefinitionSmall SampleExploratory Only
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Which subgroups of CFS patients (e.g., by oxidative stress level, symptom profile, or demographic characteristics) benefit most from this intervention?
Does Robuvit® work through oxidative stress reduction alone, or are there other mechanisms of benefit?
How does Robuvit® compare to other antioxidant interventions or symptom-management strategies in CFS?